TAK‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and Waldenström's macroglobulinemia (WM). This was the first clinical study to evaluate the safety, tolerability, maximal‐tolerated dose (MTD), dose‐limiting toxicity (DLT), pharmacokinetics, and preliminary clinical activity of TAK‐228, an oral TORC1/2 inhibitor, in patients with MM, NHL, or WM. Thirty‐nine patients received TAK‐228 once daily (QD) at 2, 4, 6, or 7 mg, or QD for 3 days on and 4 days off each week (QDx3d QW) at 9 or 12 mg, in 28‐day cycles. The overall median age was 61.0 years (range 46–85); 31 patients had MM, four NHL, and four WM. Cycle 1 DLTs occurred in five QD patients (stomatitis, urticaria, blood creatinine elevation, fatigue, and nausea and vomiting) and four QDx3d QW patients (erythematous rash, fatigue, asthenia, mucosal inflammation, and thrombocytopenia). The MTDs were determined to be 4 mg QD and 9 mg QDx3d QW. Thirty‐six patients (92%) reported at least one drug‐related toxicity; the most common grade ≥3 drug‐related toxicities were thrombocytopenia (15%), fatigue (10%), and neutropenia (5%). TAK‐228 exhibited a dose‐dependent increase in plasma exposure and no appreciable accumulation with repeat dosing; mean plasma elimination half‐life was 6–8 hr. Of the 33 response‐evaluable patients, one MM patient had a minimal response, one WM patient achieved partial response, one WM patient had a minor response, and 18 patients (14 MM, two NHL, and two WM) had stable disease. These findings encourage further studies including combination strategies. Am. J. Hematol. 91:400–405, 2016. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“The mammalian target of rapamycin (mTOR) regulates tumor cell growth, metabolism, and motility [1,2].”
BackgroundInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“Response was assessed using the International Myeloma Working Group uniform response criteria for MM [34] plus European Group for Blood and Marrow Transplantation criteria for minimal response [35], the International Working Group revised response criteria for NHL [36], and the updated Third International Workshop cri…”
MethodSelf-citationmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“mTOR operates in two distinct multiprotein complexes, target of rapamycin complex 1 and 2 (TORC1 and TORC2), in the canonical PI3K/AKT/mTOR pathway [3].”
BackgroundThe translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Liang, J., & Slingerland, J. M. (2003) · Cell Cycle · doi:10.4161/cc.2.4.433 · Cited by 885
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460 · cited 1×
“The mammalian target of rapamycin (mTOR) regulates tumor cell growth, metabolism, and motility [1,2].”
BackgroundShapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152 · cited 1×
“The incidence and severity of rash did not increase in a dose-proportional manner and were similar to rash observed with other PI3K/AKT/mTOR inhibitors [41,42].”
ResultGhobrial, I. M., Weller, E., Vij, R., Munshi, N. C., Banwait, R., Bagshaw, M., Schlossman, R., Leduc, R., Chuma, S., Kunsman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70028-6 · Cited by 95
Self-citation
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“Mucositis is also one of the main dose-limiting toxicities of the TORKi compounds (Table S1) AZD2014 (Basu et al., 2015) and CC-223 (Bendell et al., 2015a) and occurred frequently in a phase I trial of TAK-228 (Ghobrial et al., 2016).”
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00530-y · Cited by 46
Metadata
- Authors
- Ghobrial, I. M., Siegel, D. S., Vij, R., Berdeja, J. G., Richardson, P. G., Neuwirth, R., Patel, C. G., Zohren, F., & Wolf, J. L.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2016-03-18
- Volume
- 91
- Issue
- 4
- Pages
- 400-405
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2286842342
- Cited by
- 95
- References
- 11
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.